Speed, safety, and industry funding - From PDUFA i to PDUFA VI

New England Journal of Medicine

Volumn 377, Issue 23, 2017, Pages 2278-2286

  Darrow, Jonathan J ^a   Avorn, Jerry ^a   Kesselheim, Aaron S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; DRUG APPROVAL; DRUG INDUSTRY; DRUG LEGISLATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FUNDING; HEALTH CARE NEED; HEALTH CARE POLICY; HUMAN; MEDICAL PRACTICE ACT; PRESCRIPTION DRUG USER FEE ACT; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; ECONOMICS; HISTORY; LEGISLATION AND JURISPRUDENCE; UNITED STATES;

DRUG APPROVAL; DRUG INDUSTRY; HEALTH POLICY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85038249885     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMhle1710706     Document Type: Review

References (78)

1. Pub. L. No. 115-52, 131 Stat. 1005 (Aug. 18, 2017).
2. Zelenay JL Jr. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration? Food Drug Law J 2005; 60: 261-338.
3. Kusserow RP. Implementing user fees in the Food and Drug Administration: a case study. Washington, DC: Office of the Inspector General, July 1990 (https://oig.hhs.gov/oei/reports/oei-12-90-02020.pdf).
4. Woodcock J, Junod S. PDUFA lays the foundation: launching into the era of user fee acts. Silver Spring, MD: Food and Drug Administration (https://www.fda.gov/aboutfda/whatwedo/history/overviews/ucm305697.htm).
5. H.R. Rep. 102-895, 102d Cong., 2d Sess. (Sept. 22, 1992).
6. Drug Amendments of 1962, Pub. L. No. 87-781, § 104, 76 Stat. 780, 784 (1962).
7. FDA drug approval - a lengthy process that delays the availability of important new drugs. HRD 80-64. Washington, DC: Government Accountability Office, May 28, 1980 (http://www.gao.gov/products/HRD-80-64).
8. Hearing before the Subcommittee on Health and the Environment, of the Committee on Energy and Commerce, U.S. House of Representatives. 102d Cong., 2d Sess. (Aug. 10, 1992).
9. Hilts PJ. Protecting America's health: the FDA, business, and one hundred years of regulation. New York: Alfred A. Knopf, 2003.
10. The Food and Drug Administration's process for approving new drugs: report prepared by the Subcommittee on Science, Research, and Technology of the Committee on Science and Technology, U.S. House of Representatives. 96th Cong., 2d Sess., at 17 (Nov. 1980).
11. Government Accountability Office. FDA drug approval: review time has decreased in recent years. PEMD-96-1. October 20, 1995 (http://www.gao.gov/products/PEMD-96-1).
12. Prescription Drug User Fee Act of 1992, 138 Cong. Rec. 9095-100 (Sept. 22, 1992).
13. Hearing of the Committee on Labor and Human Resources. U.S. Senate. 102d Cong., 2d Sess. (Sept. 22, 1992) (statement of David Kessler, FDA Commissioner).
14. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal. Clinical development success rates for investigational drugs. Nat Biotechnol 2014; 32: 40-51.
15. Performance goals for the Prescription Drug User Fee Act of 1997, 143 Cong. Rec. S12653-S12656 (1997).
16. Prescription Drug User Fee Act (PDUFA): adding resources nd improving performance in FDA review of new drug applications. White paper. Silver Spring, MD: Food and Drug Administration, 2005 (https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM149130.pdf).
17. S. Rep. No. 105-43, 105th Cong., 1st Sess. 54 (1997).
18. Performance goals for the prescription drug user fee act of 2002. 148 Cong. Rec. S5195-S5200 (2002).
19. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
20. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81.
21. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA 2006; 296: 1653-6.
22. Avorn J. Powerful medicines. New York: Alfred A. Knopf, 2004.
23. FDA Amendments Act of 2007, Pub. L. No. 110-85, 121 Stat. 823, 828 (2007).
24. Performance goals for the Prescription Drug User Fee Act of 2007. 153 Cong. Rec. S12421-S12428 (2007).
25. 21 C.F.R. § 314.101(a)(1) (2016).
26. MDUFA performance goals and procedures. 158 Cong. Rec. S8277-S8281.
27. FDA Safety and Innovation Act, Pub. L. No. 112-144, 126 Stat. 993, 997 (2012).
28. Hearing before the Subcommittee on Health of the Committee on Energy and Commerce. U.S. House of Representatives. 107th Cong., 2d Sess., at 13, 27 (Mar. 6, 2002).
29. Thompson L. User fees for faster drug review: are they helping or hurting the public health? FDA Consumer Magazine. September- October 2000 (https://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/features/2000/500-pdufa.html).
30. Medical Device User Fee and Modernization Act of 2002, Pub. L. No. 107-250, §§ 101- 107, 116 Stat. 1588 (2002) (codified as amended at 21 U.S.C. §§ 379i, 379j (2013)).
31. Food and Drug Administration. Other fee related questions. January 19, 2017 (https://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/ucm319572.htm).
32. Prescription drug user fee rates for fiscal year 2018. Fed Regist 2017; 82(177): 43244-8.
33. Generic drug user fee rates for fiscal year 2018. Fed Regist 2017; 82(166): 41026-9.
34. Medical device user fee rates for fiscal year 2018. Fed Regist 2017; 82(166): 41029-35.
35. Biosimilar user fee rates for fiscal year 2018. Fed Regist 2017; 82(177): 43241-3.
36. Food and Drug Administration. PDUFA reauthorization performance goals and procedures fiscal years 2018 through 2022 (https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM511438.pdf).
37. Center for Drug Evaluation and Research. Manual of policies and procedures 5240.3 rev. 2. Rockville, MD: Food and Drug Administration, March 11, 2016.
38. 21 C.F.R. § 314.70(b)(4) (2016).
39. Food and Drug Administration. CDER approval times for priority and standard NDAs and BLAs: calendar years 1993-2016 (https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/UCM540942.pdf).
40. Food and Drug Administration. FY 2003 PDUFA performance report (https://wayback.archive-it.org/7993/20170406002505/https://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/ucm115144.htm).
41. Food and Drug Administration. FY 2005: performance report to the President and the Congress for the Prescription Drug User Fee Act (https://wayback.archive-it.org/7993/20170113075535/http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/ucm095108.pdf).
42. 163 Cong. Rec. S2838 (2017).
43. Food and Drug Administration. FY 1997 PDUFA financial report (https://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/FinancialReports/PDUFA/ucm135164.htm).
44. Food and Drug Administration. FY 2016 PDUFA financial report (https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/FinancialReports/PDUFA/UCM550408.pdf).
45. User fees. 163 Cong. Rec. S2953 (2017).
46. Food and Drug Administration user fee reauthorization. Cong. Rec. S1886-S1887 (2017).
47. Food and Drug Administration. Operating plan for FY 2016 (https://www.fda.gov/downloads/AboutFDA/ReportsManuals-Forms/Reports/BudgetReports/UCM482760.pdf).
48. Animal Drug User Fee Act of 2003, Pub. L. No. 108-130, 117 Stat. 1361 (2003) (codified as amended at 21 U.S.C. §§ 379j-11, j-12).
49. FDA Modernization Act of 1997, Pub. L. No. 105-115, § 101(4), 111 Stat. 2296, 2298 (1997).
50. Public Health Security and Bioterrorism Preparedness and Response Act of 2002, Pub. L. No. 107-188, § 505, 116 Stat. 594, 692 (2002).
51. Medical device user fee amendments. (MDUFA IV). August 21, 2017 (https://www.fda.gov/forindustry/userfees/medicaldeviceuserfee/ucm454039.htm).
52. Food and Drug Administration. GDUFA reauthorization public meetings. January 9, 2017 (https://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/ucm444958.htm).
53. Food and Drug Administration. BsUFA meetings. November 9, 2017 (https://www.fda.gov/forindustry/userfees/biosimilaruserfeeactbsufa/ucm461774.htm).
54. Carpenter D. Corrosive capture? The dueling forces of autonomy and industry influence in FDA pharmaceutical regulation. In: Carpenter D, Moss DA, eds. Preventing regulatory capture: special interest influence and how to limit it. New York: Cambridge University Press, 2014: 152-72.
55. Kwak J. Cultural capture and the financial crisis. In: Carpenter D, Moss DA, eds. Preventing regulatory capture: special interest influence and how to limit it. New York: Cambridge University Press, 2014: 71-98.
56. Baciu A, Stratton K, Burke SP, eds. The future of drug safety: promoting and protecting the health of the public. Bethesda, MD: Institute of Medicine, 2007.
57. Union of Concerned Scientists. Voices of scientists at FDA: protecting public health depends on independent science. 2006 (http://www.ucsusa.org/our-work/center-science-and-democracy/promoting-scientific-integrity/summary-of-the-fda-scientist.html#.WSRpOZLysuo).
58. Office of the Inspector General. FDA's review process for new drug applications: a management review. Bethesda, MD: Department of Health & Human Services, March 2003. (Publication no. OEI-01-01-00590) (https://oig.hhs.gov/oei/reports/oei-01-01-00590.pdf).
59. Wolfe S, Lurie P, Dooley B. FDA medical officers report falling standards, permit dangerous drug approval: heavy pressure from industry and FDA hierarchy cited. Public Citizen. December 2, 1998 (https://www.citizen.org/sites/default/files/1466.pdf).
60. 153 Cong. Rec. 10732 (2007).
61. Abola MV, Prasad V. Industry funding of cancer patient advocacy organizations. Mayo Clin Proc 2016; 91: 1668-70.
62. Rose SL, Highland J, Karafa MT, Joffe S. Patient advocacy organizations, industry funding, and conflicts of interest. JAMA Intern Med 2017; 177: 344-50.
63. Hutt PB. The state of science at the Food and Drug Administration. Adm Law Rev 2008; 60: 431-86.
64. Gilhooley M. Drug user fee reform: the problem of capture and a sunset, and the relevance of priorities and the deficit. N M Law Rev 2011; 41: 327-59.
65. O'Leary P. Funding the FDA: assessing the user fee provisions of the FDA Safety and Innovation Act of 2012. Harv J Legis 2013; 50: 239-61.
66. Darrow JJ. Pharmaceutical efficacy: the illusory legal standard. Wash Lee Law Rev 2013; 70: 2073-136.
67. Tan A, Porcher R, Crequit P, et al. Differences in treatment effect size between overall survival and progression-free survival in immunotherapy trials: a meta-epidemiologic study of trials with results posted at ClinicalTrials.gov. J Clin Oncol 2017; 35: 1686-94.
68. Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med 2015; 175: 1389-98.
69. Ciani O, Buyse M, Garside R, et al. Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. BMJ 2013; 346: f457.
70. Food and Drug Administration. Adaptive design clinical trials for drugs and biologics: guidance for industry (draft). February 2010 (https://www.fda.gov/downloads/drugs/guidances/ucm201790.pdf).
71. Food and Drug Administration. Multiple endpoints in clinical trials: guidance for industry (draft). January 2017 (https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm536750.pdf).
72. Chow SC, Chang M. Adaptive design methods in clinical trials - a review. Orphanet J Rare Dis 2008; 3: 11.
73. Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med 2016; 176: 1826-33.
74. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med 2008; 358: 1354-61.
75. Frank C, Himmelstein DU, Woolhandler S, et al. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals. Health Aff (Millwood) 2014; 33: 1453-9.
76. Stern AD, Kramer DB, Ouellet M, Kesselheim AS. Review times and adverse events for cardiovascular devices. Nat Biomed Eng 2017; 1: e1-e3.
77. Kesselheim AS, Woloshin S, Eddings W, Franklin JM, Ross KM, Schwartz LM. Physicians' knowledge about FDA approval standards and perceptions of the "breakthrough therapy" designation. JAMA 2016; 315: 1516-8.
78. Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017; 377: 1114-7.